Trial Profile

An open-label, multicenter, phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate (ARX305) for injection in patients with advanced cancer.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARX 305 (Primary)
Indications Haematological malignancies; Lymphoma; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man

09 Nov 2022 Accordig to an Ambrx media release, first patient has been dosed in this trial.
09 Nov 2022 Status changed from planning to recruiting, according to an Ambrx media release.
01 Jul 2022 Accordig to an Ambrx media release, In July, Ambrxs partner in China, NovoCodex, announced that it had received drug clinical trial approval notice for ARX305 and intends to initiate this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com